Bitcoin Tracker One Opens a Dollar-Quoted Route for U.S. Investors

Bitcoin Tracker One became quoted in U.S. dollars under the ticker CXBTF on August 15, 2018, creating a new route for some American brokerage customers to obtain bitcoin-linked exposure without buying or securing bitcoin directly.

The development was narrower than the arrival of a U.S.-listed bitcoin exchange-traded fund. Bitcoin Tracker One remained a Swedish instrument listed on Nasdaq Stockholm and issued by XBT Provider AB. Bloomberg reported on August 15 that the dollar quotation would help brokerages make the product available to American investors, even though its listing and regulation remained in Sweden.

That distinction mattered. The quotation reduced currency and operational friction for eligible U.S. customers, but it did not represent Securities and Exchange Commission approval of a domestic bitcoin ETF, confer the protections associated with such an approval or guarantee that every brokerage would permit purchases.

A foreign instrument, not a U.S. ETF

Nasdaq Stockholm had introduced Bitcoin Tracker One in May 2015 as a tracker certificate using bitcoin as its underlying asset. The exchange described it as the first bitcoin tracker traded on a regulated exchange. The August 15, 2018 development did not create a new fund or move the instrument’s primary listing to the United States.

Instead, CXBTF was a U.S. over-the-counter quotation for the foreign security. Contemporary and later market documentation described such foreign quotations as being executed in dollars while the underlying security continued to be cleared, held and settled through its home market and currency arrangements. Investors therefore faced the structure and risks of the Swedish certificate, not shares in a U.S.-registered investment company.

Terminology was already a material limitation. News coverage commonly called Bitcoin Tracker One an exchange-traded note, while Nasdaq’s original announcement called it a tracker certificate. XBT Provider’s disclosures used the term “non-equity linked certificate.” Those descriptions were not interchangeable shorthand for a U.S. ETF.

Why the timing mattered

The dollar quotation arrived amid an unresolved U.S. debate over exchange-traded bitcoin products. On July 26, 2018, the SEC disapproved the proposed rule change for the Winklevoss Bitcoin Trust. On August 7, the agency extended its review period for Cboe BZX’s proposal involving the VanEck SolidX Bitcoin Trust.

Against that backdrop, CXBTF offered a partial market-access answer rather than a regulatory resolution. It allowed qualifying customers to seek bitcoin-linked exposure through a conventional brokerage interface, potentially avoiding direct management of private keys. It did not remove issuer credit risk, tracking risk, liquidity constraints, brokerage restrictions or exposure to bitcoin’s price.

The verified record does not establish how many U.S. investors could trade CXBTF on August 15, what volume changed hands during the session or whether the quotation materially affected bitcoin’s market price. No causal market claim is warranted from the available evidence.

Later context: the structure drew scrutiny

Later events clarify the limitations without changing what was knowable on August 15. On September 9, 2018, the SEC temporarily suspended U.S. trading in CXBTF and the related Ether Tracker One quotation, citing a lack of current, consistent and accurate information and confusion over whether the instruments were ETFs, notes or certificates.

In a September 20 staff statement, the SEC confirmed that the securities were listed on Nasdaq/OMX in Stockholm and had recently been quoted on OTC Link. The staff also summarized issuer disclosures stating that the certificates bore no interest, were not principal-protected and had no scheduled maturity date.

The August 15 development was therefore significant as an experiment in cross-border bitcoin market access, not as a substitute for U.S. ETF approval. This reconstruction describes the instrument according to the evidence available for the date and separately labels the regulatory clarification that followed.